glucagon has been researched along with ranolazine in 2 studies
Studies (glucagon) | Trials (glucagon) | Recent Studies (post-2010) (glucagon) | Studies (ranolazine) | Trials (ranolazine) | Recent Studies (post-2010) (ranolazine) |
---|---|---|---|---|---|
26,039 | 1,498 | 3,054 | 799 | 104 | 498 |
Protein | Taxonomy | glucagon (IC50) | ranolazine (IC50) |
---|---|---|---|
Sodium channel protein type 5 subunit alpha | Homo sapiens (human) | 6.85 | |
Voltage-gated sodium channel Nav1.5 cardiac isoform | Canis lupus familiaris (dog) | 6.9 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Taegtmeyer, H | 1 |
Belardinelli, L; Dhalla, AK; Kahlig, KM; Krause, M; Ning, Y; Rajamani, S; Yang, M | 1 |
2 other study(ies) available for glucagon and ranolazine
Article | Year |
---|---|
Cardiac metabolism as a target for the treatment of heart failure.
Topics: Acetanilides; Animals; Dogs; Energy Metabolism; Epoxy Compounds; Fatty Acids; Forecasting; Glucagon; Glucagon-Like Peptide 1; Glucose; Heart Failure; Humans; Insulin Resistance; Myocardium; Peptide Fragments; Piperazines; Protein Precursors; Ranolazine; Recombinant Proteins | 2004 |
Blockade of Na+ channels in pancreatic α-cells has antidiabetic effects.
Topics: Acetanilides; Animals; Diabetes Mellitus, Experimental; Exocytosis; Glucagon; Glucagon-Secreting Cells; Humans; Hypoglycemic Agents; Islets of Langerhans; Male; NAV1.3 Voltage-Gated Sodium Channel; Piperazines; Ranolazine; Rats; Rats, Sprague-Dawley; Sodium Channel Blockers | 2014 |